Actinium unveils first-in-human ATNM 400 data in prostate cancer at EANM 2026
Actinium Pharmaceuticals, Inc. , a pioneer in differentiated targeted radiotherapies with the potential to transform cancer treatment, today announced encouraging initial clinical results from the first‑in‑human Phase 1… read more.
